Skip to main content
Prelude Therapeutics Inc logo

Prelude Therapeutics Inc — Investor Relations & Filings

Ticker · PRLD ISIN · US74065P1012 US Manufacturing
Open in API
Filings indexed 356 across all filing types
Latest filing 2021-06-22 Director's Dealing
Country US United States of America
Listing US PRLD

About Prelude Therapeutics Inc

https://preludetx.com/

Prelude Therapeutics is a clinical-stage precision oncology company focused on discovering and developing innovative medicines for cancer patients with high unmet needs. The company's pipeline features small molecule therapies and leverages expertise in targeted protein degradation. Key development programs include highly selective KAT6A degraders for solid tumors, such as ER+ breast cancer, and mutant-selective JAK2V617F JH2 inhibitors for myeloproliferative neoplasms. Prelude is also advancing next-generation degrader antibody conjugates (DACs) with novel payloads. The company's science-driven approach targets critical cancer cell pathways to create potentially transformative treatments.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-06-22 English
PRIMARY DOCUMENT
Director's Dealing
2021-06-22 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 18, 2021. It reports the submission of matters to a vote of security holders at the company's 2021 Annual Meeting of Stockholders. The content includes election results of directors and ratification of the independent auditor. There are no financial statements or detailed financial data, only voting results. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3554 characters, which is short but contains substantive voting results, not just an announcement of a report. Therefore, the correct classification is DVA with high confidence.
2021-06-22 English
FORM 4 SUBMISSION
Director's Dealing
2021-06-10 English
FORM 4 SUBMISSION
Director's Dealing
2021-05-27 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 12, 2021, for Prelude Therapeutics Incorporated. The key content is an investor presentation attached as Exhibit 99.1, which is described as materials to be used in investor presentations. The document explicitly states that the presentation is attached and incorporated by reference, and the main body of the filing is a brief disclosure rather than a full report. The length is 3454 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, when a document is short and primarily announces or attaches an investor presentation, it should be classified as Investor Presentation (IP).
2021-05-12 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.